251 related articles for article (PubMed ID: 31610342)
1. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.
Wagner DA; Kelly SM; Petersen AC; Peroutka-Bigus N; Darling RJ; Bellaire BH; Wannemuehler MJ; Narasimhan B
Acta Biomater; 2019 Dec; 100():326-337. PubMed ID: 31610342
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial Viral Vector-Based and Live Attenuated Vaccines without an Adjuvant to Generate Broader Immune Responses to Effectively Combat Pneumonic Plague.
Kilgore PB; Sha J; Hendrix EK; Motin VL; Chopra AK
mBio; 2021 Dec; 12(6):e0322321. PubMed ID: 34872353
[TBL] [Abstract][Full Text] [Related]
3. Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination.
Derbise A; Hanada Y; Khalifé M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2015; 9(10):e0004162. PubMed ID: 26473734
[TBL] [Abstract][Full Text] [Related]
4. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague.
Bowen W; Batra L; Pulsifer AR; Yolcu ES; Lawrenz MB; Shirwan H
Vaccine; 2019 Sep; 37(38):5708-5716. PubMed ID: 31416643
[TBL] [Abstract][Full Text] [Related]
5. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.
Boyer JL; Sofer-Podesta C; Ang J; Hackett NR; Chiuchiolo MJ; Senina S; Perlin D; Crystal RG
Hum Gene Ther; 2010 Jul; 21(7):891-901. PubMed ID: 20180652
[TBL] [Abstract][Full Text] [Related]
6. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine.
Erova TE; Rosenzweig JA; Sha J; Suarez G; Sierra JC; Kirtley ML; van Lier CJ; Telepnev MV; Motin VL; Chopra AK
Clin Vaccine Immunol; 2013 Feb; 20(2):227-38. PubMed ID: 23239803
[TBL] [Abstract][Full Text] [Related]
8. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases.
Ulery BD; Kumar D; Ramer-Tait AE; Metzger DW; Wannemuehler MJ; Narasimhan B
PLoS One; 2011 Mar; 6(3):e17642. PubMed ID: 21408610
[TBL] [Abstract][Full Text] [Related]
9. Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines.
Tao P; Mahalingam M; Kirtley ML; van Lier CJ; Sha J; Yeager LA; Chopra AK; Rao VB
PLoS Pathog; 2013; 9(7):e1003495. PubMed ID: 23853602
[TBL] [Abstract][Full Text] [Related]
10. Protection against pneumonic plague following oral immunization with a non-replicating vaccine.
Jones A; Bosio C; Duffy A; Goodyear A; Schriefer M; Dow S
Vaccine; 2010 Aug; 28(36):5924-9. PubMed ID: 20600517
[TBL] [Abstract][Full Text] [Related]
11. Sex differences in immune protection in mice conferred by heterologous vaccines for pneumonic plague.
Davies ML; Biryukov SS; Rill NO; Klimko CP; Hunter M; Dankmeyer JL; Miller JA; Shoe JL; Mlynek KD; Talyansky Y; Toothman RG; Qiu J; Bozue JA; Cote CK
Front Immunol; 2024; 15():1397579. PubMed ID: 38835755
[TBL] [Abstract][Full Text] [Related]
12. Complete Protection Against
Zhang W; Song X; Zhai L; Guo J; Zheng X; Zhang L; Lv M; Hu L; Zhou D; Xiong X; Yang W
Front Immunol; 2022; 13():793382. PubMed ID: 35154110
[TBL] [Abstract][Full Text] [Related]
13. Lung deposition and cellular uptake behavior of pathogen-mimicking nanovaccines in the first 48 hours.
Ross KA; Haughney SL; Petersen LK; Boggiatto P; Wannemuehler MJ; Narasimhan B
Adv Healthc Mater; 2014 Jul; 3(7):1071-7. PubMed ID: 24520022
[TBL] [Abstract][Full Text] [Related]
14. Single-dose intranasal subunit vaccine rapidly clears secondary sepsis in a high-dose pneumonic plague infection.
D'Arco C; McCormick AA; Arnaboldi PM
Vaccine; 2021 Mar; 39(9):1435-1444. PubMed ID: 33531196
[TBL] [Abstract][Full Text] [Related]
15. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.
Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB
mBio; 2018 Oct; 9(5):. PubMed ID: 30327445
[No Abstract] [Full Text] [Related]
16. Development of Yersinia pestis F1 antigen-loaded microspheres vaccine against plague.
Huang SS; Li IH; Hong PD; Yeh MK
Int J Nanomedicine; 2014; 9():813-22. PubMed ID: 24550673
[TBL] [Abstract][Full Text] [Related]
17. Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague.
Yang X; Hinnebusch BJ; Trunkle T; Bosio CM; Suo Z; Tighe M; Harmsen A; Becker T; Crist K; Walters N; Avci R; Pascual DW
J Immunol; 2007 Jan; 178(2):1059-67. PubMed ID: 17202369
[TBL] [Abstract][Full Text] [Related]
18. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.
Yamanaka H; Hoyt T; Yang X; Golden S; Bosio CM; Crist K; Becker T; Maddaloni M; Pascual DW
Infect Immun; 2008 Oct; 76(10):4564-73. PubMed ID: 18694965
[TBL] [Abstract][Full Text] [Related]
19. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J
Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064
[TBL] [Abstract][Full Text] [Related]
20. An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague.
Derbise A; Cerdà Marín A; Ave P; Blisnick T; Huerre M; Carniel E; Demeure CE
PLoS Negl Trop Dis; 2012; 6(2):e1528. PubMed ID: 22348169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]